D.E. Shaw & Co’s United Therapeutics UTHR Stock Holding History

D.E. Shaw & Co’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,200	Closed	-$585K	–	5090
2025 Q4	$585K	Sell	1,200 -1,600	-57%	-$745K	﹤0.01%	3853
2025 Q3	$1.17M	Buy	+2,800	New	+$942K	﹤0.01%	3359
2025 Q1	–	Sell	-1,500	Closed	-$529K	–	4778
2024 Q4	$529K	Buy	+1,500	New	+$551K	﹤0.01%	3587
2022 Q1	–	Sell	-5,600	Closed	-$1.21M	–	5959
2021 Q4	$1.21M	Buy	+5,600	New	+$1.1M	﹤0.01%	3773
2017 Q1	–	Sell	-20,000	Closed	-$2.87M	–	3624
2016 Q4	$2.87M	Hold	20,000	–	–	﹤0.01%	1740
2016 Q3	$2.36M	Hold	20,000	–	–	﹤0.01%	1803
2016 Q2	$2.12M	Hold	20,000	–	–	﹤0.01%	1896
2016 Q1	$2.23M	Hold	20,000	–	–	﹤0.01%	1811
2015 Q4	$3.13M	Hold	20,000	–	–	﹤0.01%	1788
2015 Q3	$2.63M	Hold	20,000	–	–	﹤0.01%	1891
2015 Q2	$3.48M	Buy	20,000 +10,000	+100%	+$1.8M	0.01%	1757
2015 Q1	$1.72M	Buy	+10,000	New	+$1.52M	﹤0.01%	2140
2014 Q1	–	Sell	-20,000	Closed	-$2.26M	–	4644
2013 Q4	$2.26M	Sell	20,000 -20,000	-50%	-$1.8M	﹤0.01%	2407
2013 Q3	$3.15M	Buy	+40,000	New	+$2.92M	0.01%	2024

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

D.E. Shaw & Co's UTHR Position: Q2 2026 in Review

D.E. Shaw & Co sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 99,106 shares — an estimated $58.8M sold.

D.E. Shaw & Co first reported a position in UTHR in Q4 2013 and held it in 48 quarters. The position peaked at $150M in Q4 2025. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

D.E. Shaw & Co reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
D.E. Shaw & Co sold 99,106 United Therapeutics shares in Q2 2026, an estimated $58.8M.
D.E. Shaw & Co first reported a position in United Therapeutics in Q4 2013 and held it in 48 quarters.
D.E. Shaw & Co's United Therapeutics position peaked at $150M in Q4 2025.
880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.